What screening approach could improve early detection of ‘at-risk’ metabolic dysfunction–associated steatohepatitis in my patients?

What screening approach could improve early detection of 'at-risk' metabolic dysfunction-associated steatohepatitis in my patients? Q:A 54-year-old woman with type 2 diabetes mellitus (hemoglobin A1c 8.1%), body mass index 34 kg/m2, and hypertension presents for routine follow-up of her cardiometabolic diseases.Should she be screened for advanced liver fi brosis due to metabolic dysfunction-associated steatohepatitis (MASH), and what is the recommended approach to risk stratifi cation?'AT-RISK' MASH SCREENING